# Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1

> **NCT06649474** · NA · RECRUITING · sponsor: **University Hospital, Clermont-Ferrand** · enrollment: 100 (estimated)

## Conditions studied

- Pancreatic Cancer
- Resectable Pancreatic Adenocarcinoma
- Adenocarcinoma
- Resectable Esophageal Cancer
- Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Oesophagogastric Cancer

## Interventions

- **BIOLOGICAL:** assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy

## Key facts

- **NCT ID:** NCT06649474
- **Lead sponsor:** University Hospital, Clermont-Ferrand
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-06
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649474, "Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06649474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*